View Cart  

NovaBay Pharmaceuticals Receives $2.6 Million From Partner Galderma

A A
NovaBay Pharmaceuticals, a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides, today announced that it has received $2.6 million from partner Galderma S.A., a global leading pharmaceutical company exclusively focused on dermatology.
Equities